Form 8-K - Current report:
SEC Accession No. 0001641172-25-005427
Filing Date
2025-04-18
Accepted
2025-04-18 16:30:21
Documents
14
Period of Report
2025-04-18
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47206
  Complete submission text file 0001641172-25-005427.txt   285384

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE asbp-20250418.xsd EX-101.SCH 3831
3 XBRL DEFINITION FILE asbp-20250418_def.xml EX-101.DEF 28307
4 XBRL LABEL FILE asbp-20250418_lab.xml EX-101.LAB 37864
5 XBRL PRESENTATION FILE asbp-20250418_pre.xml EX-101.PRE 26519
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7384
Mailing Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791
Business Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 25850664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)